AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04134247
Drug: chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rituximab 375mg/m2，d0（ Except for patients who relapsed within12 months after the last application of rituximab）~The chemotherapy chooses one of the following:~GDP：Gemcitabine 800-1000mg/m2, d1、8; Cisplatin 25mg/m2, d1-3; Dexamethasone 40mg, d1-4; GemOx：Gemcitabine 800-1000mg/m2, d1、8; Oxaliplatin 130mg/m2，d1; DA-EPOCH：Epirubicin 15mg／m２ ,d1-4; Etoposide 50mg／m２ ,d1-4; Vincristine 0.4mg/ ｍ２ ，d1-4; Cyclophosphamide 750mg/ ｍ２ , d５; Prednisone 60mg/m２/d, d1-5; ICE: Ifosfamide 1g/m２，d1-4; Cisplatin 25mg/m２, d1-4; Etoposide 60 mg／m２，d1-4; DICE: Ifosfamide 1 g／m２，dl-d4; Cisplatin 25mg/m２, d1-4; Etoposide 60 mg／m２，d1-4; Dexamethasone 10-20mg，d1-4; High dose MTX（Central recurrence）：MTX 3.5g／ｍ２,ｄ1; Hyper CVAD（B）：MTX 1g／ｍ２, d1; Cytarabine 2-3g／ｍ２, q12h, d2-3
Trial: NCT02345772
Drug: Pertuzumab (P, 840 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trastuzumab (H, 8mg/kg for 1st cycle, then 6 mg/kg in subsequent cycles before and after surgery), pertuzumab (P, 840 mg for 1st cycle, then 420 mg in subsequent 3 cycles) will be given concurrently with docetaxel for a total of 4 cycles before surgery.
Trial: NCT01170065
Drug: BIBF 1120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermediate dose BIBF 1120 twice daily
Trial: NCT01170065
Drug: BIBF 1120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose BIBF 1120 twice daily
Trial: NCT01170065
Drug: BIBF 1120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose BIBF 1120 twice daily
Trial: NCT01170065
Drug: BIBF 1120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose BIBF 1120 once daily
Trial: NCT01913028
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1st cohort : Dose 1 MEDI9929 or placebo 2nd cohort : Dose 2 MEDI9929 or placebo 3rd cohort : Dose 3 MEDI9929 or placebo
Trial: NCT03042377
Drug: Multiple-Visit-Calcium Hydroxide
RxNorm normalized name: Calcium Hydroxide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The teeth in this group were treated according to the guidelines for root canal retreatment in multiple-session. The filling was removed and cavity was opened. Then root canal filling was removed from the root canals completely using retreatment kit. After irrigation protocol, root canals were treated with calcium hydroxide and the cavity was filled with temporary restorative material.
Trial: NCT03042377
Drug: Multiple-Visit-Antibiotic Paste
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The teeth in this group were treated according to the guidelines for root canal retreatment in multiple-session. The filling was removed and cavity was opened. Then root canal filling was removed from the root canals completely using retreatment kit. After irrigation protocol, root canals were treated with an antibiotic paste and the cavity was filled with temporary restorative material.
Trial: NCT00770042
Drug: Erythomycin
RxNorm normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Erythromycin 500 mg every 12 hours for 5 days (Days 2-6)
Trial: NCT01151735
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT03933410
Drug: KB195
RxNorm normalized name: Ketobemidone
DrugBank: Ketobemidone (DB06738)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KB195 is a novel glycan
Trial: NCT04397913
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 10 mg/kg qd for the 1st day, 5 mg/kg qd for the 2nd and 3rd day
Trial: NCT00686322
Drug: Concurrent chemoradiotherapy (paclitaxel plus cisplatin plus radiotherapy)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction one cycle of paclitaxel plus cisplatin (PC), concurrent 2 cycles of PC with radiotherapy, followed by 2 cycles of PC consolidation chemotherapy.
Trial: NCT01716338
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00025428
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00025428
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02692040
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% saline
Trial: NCT04084548
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perioperative placebo infusion (normal saline)
Trial: NCT01760330
Drug: IV acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01760330
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01476189
Drug: Experimental paracetamol formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: experimental
Trial: NCT01476189
Drug: Marketed paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Marketed paracetamol
Trial: NCT01476189
Drug: Higher dose marketed paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher dose marketed paracetamol
Trial: NCT00712530
Drug: HAART
RxNorm normalized name: porcine heart preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three or more antiretroviral drugs that can fully suppress HIV RNA
Trial: NCT02579265
Drug: Intralipid® 20%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose: The targeted maximal dose is 3.0 g/kg/day. In patients already receiving parenteral nutrition (PN) before starting study treatment, the dose will either stay at 3.0 g/kg/day or be increased by 1.0 g/kg/day steps to a maximum of 3.0 g/kg/day.~Intralipid® 20% will be infused over 20 - 24 hours, as per hospital policy, at a weight based infusion rate.~Intralipid® 20% will be infused into a central or peripheral vein.
Trial: NCT04218838
Drug: Intra-articular Sacroiliac Joint Steroid Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of Care - Steroid injection into the sacroiliac joint
Trial: NCT00387413
Drug: GSK189254
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive film coated tablet of GSK189254 at 50 mcg once daily for a one week and 100 mcg once daily for the second week in Treatment Arm A.
Trial: NCT00387413
Drug: GSK189254 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive Placebo matching GSK189254 for 3 weeks in each period.
Trial: NCT00433056
Drug: stable HAART
RxNorm normalized name: porcine heart preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: continuous therapy
Trial: NCT04894643
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Concomitant to proton-radiotherapy (on the same days, within week 14-19)
Trial: NCT03087968
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control drug that is also administered with the Experimental drug, GS-4997. This drug is used in both arms.
Trial: NCT03661788
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14-day treatment interval: first week one placebo pill, second week two placebo pills
Trial: NCT01551290
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Form = solution for injection, route = IV, administered on = Weeks 0, 2, 6, 14, and 22 and for extension phase: participants treated with placebo through Week 22 will receive infliximab at Weeks 32, 34, 38, 46 and 54 and will receive placebo at Week 30.
Trial: NCT01571908
Drug: Placebo perfusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patient receives during 15 minutes a perfusion of 1 ml/kg of saline before induction of anaesthesia
Trial: NCT02120092
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7x 300mg acetylsalicylic acid placebo
Trial: NCT01550341
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2/0.5, 8/2 sublingual tabs; dosage based on medical assessment; medications taken once per day for 12 months duration.
Trial: NCT03049267
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Five patients will be supplied with placebo tablets with identical labeling as apremilast for daily use; 16 weeks.
Trial: NCT00002522
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03087968
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT04125056
Drug: Hydronidone Capsule(Specification: 30 mg / grain）
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test group
Trial: NCT04125056
Drug: Hydronidone Capsule(Specification: 15 mg / grain）
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group
Trial: NCT02368912
Drug: Placebo single dose of dose levels 1-7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral, dose escalation, healthy young male
Trial: NCT02368912
Drug: ASP1707 single dose fasted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral, healthy young male
Trial: NCT02368912
Drug: ASP1707 single dose fed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral, healthy young male
Trial: NCT02368912
Drug: Placebo multiple dose of dose levels 1-4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral, multiple dose escalation, healthy elderly male
Trial: NCT02368912
Drug: Placebo multiple dose of dose levels 1-2
RxNorm normalized name: milk of magnesia 1.2 GM Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral, multiple dose escalation, healthy pre-menopausal female
Trial: NCT02368912
Drug: Placebo parallel multiple dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral, dose escalation, healthy pre-menopausal female
Trial: NCT03691623
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral suspension for 5 days
Trial: NCT04350021
Drug: Capecitabine, Cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capecitabine 500 mg times three, Cyclophosphamide 50 mg once daily
Trial: NCT04338633
Drug: Conventional calcium hydroxide paste
RxNorm normalized name: Calcium Hydroxide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional calcium hydroxide paste (Ultracal) will be removed in second visit.
Trial: NCT04338633
Drug: Calcium hydroxide nanoparticle
RxNorm normalized name: Calcium Hydroxide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium hydroxide nanoparticle. manufactured in NanoTech. institute, will be removed in second visit.
Trial: NCT04338633
Drug: Combined Calcium hydroxide with silver nanoparticle
RxNorm normalized name: Calcium Hydroxide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined Calcium hydroxide with silver nanoparticle will be removed in second visit.
Trial: NCT01431937
Drug: GSK2018682
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active Drug
Trial: NCT01431937
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02627287
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For subcutaneously (s.c. under the skin) injection
Trial: NCT00003671
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00003671
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00003671
Drug: mercaptopurine
RxNorm normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00003671
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT05081349
Drug: Hydroxycarbamide 500 Mg Oral Capsule+L-Carnitine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy
Trial: NCT05081349
Drug: Hydroxycarbamide 500 Mg Oral Capsule
RxNorm normalized name: Hydroxycarbamide 500 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single agent
Trial: NCT05081349
Drug: L-Carnitine, 250 Mg Oral Capsule
RxNorm normalized name: L-Carnitine, 250 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single agent
Trial: NCT01304212
Drug: several drugs: morphine chloride,ropivacaine,epinephrine,ketorolac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This technique is performed intraoperatively with a 100 ml solution containing: 225 mg of ropivacaine 1% (22.5 ml) + 5 mg of morphine chloride 0.1% (5ml) + 30 mg of epinephrine 1:1000 (0.3 ml ) + ketorolac 30mg (1ml) +71 ml of 0.9% saline
Trial: NCT01304212
Drug: ropivacaine,morphine chloride,epinephrine,ketorolac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This technique is performed intraoperatively with a 100 ml solution containing: 225 mg of ropivacaine 1% (22.5 ml) + 5 mg of morphine chloride 0.1% (5ml) + 30 mg of epinephrine 1:1000 (0.3 ml ) + ketorolac 30mg (1ml) +71 ml of 0.9% saline
Trial: NCT01304212
Drug: morphine ,ketorolac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ultrasound-assisted femoral nerve block is performed and leaks intraoperatively with a 100 ml solution containing: 5 mg of morphine to 0.1% (5ml) +30 mg of ketorolac (1 ml) +96 ml of 0.9% saline.
Trial: NCT03817320
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Day 1~Dose ≥ 1 year: 60mg/m2/dose~≥ 6 months and \< 1 year: 48 mg/m2/dose~\< 6 months: 42mg/m2/dose
Trial: NCT03817320
Drug: Methotrexate (IT)
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: For patients with CNS 1 or CNS 2, on Days 1, 15, and 29
Trial: NCT03817320
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: For patients with Down syndrome only, on Days 2, 9, 16, 23, and 30 (based on dates when IT Methotrexate or Triple IT is given)
Trial: NCT00090142
Drug: Comparator: Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet administered orally as a single witnessed dose before exercise challenge
Trial: NCT04185649
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine 1000 milligrams per square meter (mg/m\^2) was administered orally twice daily on Days 1-14 of each 21-day cycle.
Trial: NCT00037817
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 400mg PO BID on days 4 through 34 of each cycle
Trial: NCT01215110
Drug: TMC207
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03926000
Drug: Control placebo (C)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets one hour before the procedure as premedication.
Trial: NCT01882010
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: saline solution daily subcutaneous injection 56 days
Trial: NCT01626118
Drug: Indomethacin
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: capsules, 40 mg, TID
Trial: NCT01626118
Drug: Indomethacin
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: capsules, 40 mg, BID
Trial: NCT01626118
Drug: Indomethacin
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: capsules, 20 mg, TID
Trial: NCT01626118
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsules
Trial: NCT01778049
Drug: BI 10773 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empagliflozin placebo
Trial: NCT01778049
Drug: BI 10773 / BI 1356
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empagliflozin / Linagliptin 25/5 mg Dose FDC active
Trial: NCT01778049
Drug: BI 10773 / BI 1356
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empagliflozin / Linagliptin 10/5 mg Dose FDC active
Trial: NCT01778049
Drug: BI 10773 / BI 1356 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empagliflozin / Linagliptin 10/5 mg Dose placebo FDC
Trial: NCT01778049
Drug: BI 10773 / BI 1356 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empagliflozin / Linagliptin 25/5 mg Dose FDC placebo
Trial: NCT01778049
Drug: BI 10773 / BI 1356 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empagliflozin / Linagliptin 10/5 mg Dose FDC placebo
Trial: NCT02249299
Drug: Sativex Oromucosal Spray
RxNorm normalized name: Castanea sative leaf extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sativex Oromucosal Spray (GW Pharma Ltd, Salisbury. UK). Each 100 microlitre spray contains: 2.7 mg delta-9-tetrahydrocannabinol (THC) and 2.5 mg cannabidiol (CBD).
Trial: NCT02249299
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02928029
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo
Trial: NCT01574898
Drug: V0474 - A mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral administration
Trial: NCT01574898
Drug: V0474 - B mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral administration
Trial: NCT01574898
Drug: V0018 - B mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral administration
Trial: NCT01574898
Drug: Niquitin® Fresh Mint 4 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral administration
Trial: NCT01900301
Drug: intranasal placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be randomized to a drug placebo, administered via nasal drops, prior to each session of exposure therapy
Trial: NCT03477851
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0,9%NaCl i.m. simultaneous with sciatic nerve block
Trial: NCT03600766
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral toltordine 4 mg plus tamsulosin 0.4 mg daily for 8 weeks.
Trial: NCT01872039
Drug: Perdipine injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV
Trial: NCT01741142
Drug: ABT-436
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects receiving ABT-436
Trial: NCT01741142
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subject receiving placebo
Trial: NCT00348907
Drug: thermal cure
RxNorm normalized name: Cocci-Cure C for Calves
FDA approved: no
EMA approved: no
PMDA approved: no
Description: thermal cure of 18 days including movement in swimming pool, mud-bath, shower, massage and thermal steam
Trial: NCT00348907
Drug: late thermal cure
RxNorm normalized name: Cocci-Cure C for Calves
FDA approved: no
EMA approved: no
PMDA approved: no
Description: thermal cure of 18 days including movement in swimming pool, mud-bath, shower, massage and thermal steam at 2 years
Trial: NCT02308527
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 250mg/m2/d IV (in the vein) on Days 1 to 5 of a 4 week cycle, for 6 cycles or until progression
Trial: NCT01818258
Drug: ZDV+3TC+LPV/r
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01564290
Drug: Placebo probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lyophilized probiotic, containing 250 mg per sachet dosage to about 2 times a day for 5 days.
Trial: NCT01382303
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo tablet three times a day
Trial: NCT00446472
Drug: Regranex®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regranex gel will be used for a total of 16 weeks
Trial: NCT00446472
Drug: Hydrogel
RxNorm normalized name: HYDROGEL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo hydrogel will be applied for 16 weeks
Trial: NCT03122353
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vehicle used as placebo
Trial: NCT03216304
Drug: 20 mg rosuvastatin calcium period 1
RxNorm normalized name: rosuvastatin calcium 20 MG
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Rosuvastatin will be administered as follows:~- Day 1: a single dose of 20 mg rosuvastatin calcium (one Crestor® tablet)
Trial: NCT03216304
Drug: 20 mg rosuvastatin calcium period 2
RxNorm normalized name: rosuvastatin calcium 20 MG
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: - Day 12: a single dose of 20 mg rosuvastatin calcium (one Crestor® tablet) immediately after the safinamide administration
Trial: NCT03664674
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intratympanic injection of placebo
Trial: NCT02526823
Drug: R-CHOP/CHOPE or ABVD chemotherapy regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R-CHOP:~Rituximab：375mg/m2，ivgtt，D0； Epirubicin：70 mg/m2，ivgtt，D1 ； Cyclophosphamide：750 mg/m2，ivgtt，D1； Vincristine: 1.4 mg/m2 ivgtt，D1 ； Prednison：100mg/d，po，D1-5；~CHOPE:~Epirubicin：70 mg/m2，ivgtt，D1 ； Cyclophosphamide：750 mg/m2，ivgtt，D1； Vincristine: 1.4 mg/m2 ivgtt，D1 ； Prednison：100mg/d，po，D1-5； Etoposide: 100 mg/（m2•d），ivgtt，D1-3;~ABVD:~Epirubicin：35 mg/m2，ivgtt，D1、15； Bleomycin：10 mg/m2，ivgtt，D1、15； Vincristine：1.4 mg/m2，ivgtt，D1、15； Dacarbazine：375mg/m2，ivgtt，D1、15；